ライフサイエンスコーパス: farnesyl pyrophosphate

1 e or geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate.

2 formed both caryophyllene and humulene from farnesyl pyrophosphate.

3 es, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate.

4 generated by the sesquiterpene synthase from farnesyl pyrophosphate.

5 oid, geranylgeranyl pyrophosphate and not by farnesyl pyrophosphate.

6 finity labeling with a 32P-labeled analog of farnesyl pyrophosphate.

7 urs) in the absence (control) or presence of farnesyl pyrophosphate (10 muM) or geranylgeranyl pyroph

8 Because of the metabolic importance of farnesyl pyrophosphate, a 15-carbon (C15) intermediate o

9 Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis

10 Enzyme assays have revealed that the farnesyl pyrophosphate analogue is an inhibitor of FTase

11 analyses of cell lysates, indicate that the farnesyl pyrophosphate analogue penetrates the cells as

12 d nonracemic forms, to provide a new type of farnesyl pyrophosphate analogue.

13 tidic acid receptor with weaker responses to farnesyl pyrophosphate and geranylgeranyl diphosphate.

14 gly, the levels of the cholesterol precursor farnesyl pyrophosphate and its derivative geranylgeranyl

15 PS-induced iNOS expression by mevalonate and farnesyl pyrophosphate and reversal of the inhibitory ef

16 odel of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate)

17 rnesol, the natural dephosphorylated form of farnesyl pyrophosphate, and N-acetyl-S-trans,trans-farne

18 including mevalonate, geranyl pyrophosphate, farnesyl pyrophosphate, and ubiquinone, failed to signif

19 The phosphorylation of farnesyl pyrophosphate appears to occur in vivo as cells

20 nic acid (the product of HMG-coenzyme A) and farnesyl-pyrophosphate but not by geranyl-geranylpyropho

21 y hydroxymethylglutaryl-CoA, mevalonate, and farnesyl pyrophosphate, but not cholesterol and ubiquino

22 The phosphorylation of farnesyl pyrophosphate by Nm23 proteins could alter isop

23 The phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins provides a nove

24 gesting that [(3)H]F-OH was incorporated via farnesyl pyrophosphate (F-P-P).

25 l-P), dolichyl pyrophosphate (dolichyl-P-P), farnesyl pyrophosphate (farnesyl-P-P), and geranylgerany

26 We describe the design and synthesis of a farnesyl pyrophosphate (FPP) analogue, 8-anilinogeranyl

27 pyrophosphate (BnPP) series of transferable farnesyl pyrophosphate (FPP) analogues (1a-e) to test th

28 he synthesis of the wound-healing inhibitors farnesyl pyrophosphate (FPP) and cortisol, ligands for t

29 by depleting mevalonate pathway metabolites farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos

30 multaneously determine the concentrations of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos

31 The isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos

32 sing the X-ray crystallographic structure of farnesyl pyrophosphate (FPP) bound to the target enzyme,

33 hese events were significantly attenuated by farnesyl pyrophosphate (FPP) but not by geranylgeranyl p

34 of the 15-carbon sterol pathway intermediate farnesyl pyrophosphate (FPP) cause increased Hmg2p ubiqu

35 ructure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat F

36 We apply this approach to regulate farnesyl pyrophosphate (FPP) production in the isoprenoi

37 tes in mevalonate-depleted cells reveal that farnesyl pyrophosphate (FPP) restores Ras processing and

38 roposed for the carbocationic cyclization of farnesyl pyrophosphate (FPP) to (+)-aristolochene cataly

39 ules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to generate the C(55) undec

40 We synthesized analogues (3-6) of farnesyl pyrophosphate (FPP) to probe the range of modif

41 se (FPTase) transfers the farnesyl moiety of farnesyl pyrophosphate (FPP) to the thiol of the CaaX bo

42 from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to their protein or peptide

43 Farnesyl pyrophosphate (FPP), a key intermediate in the

44 of mevalonate or its isoprenoid derivative, farnesyl pyrophosphate (FPP), prevented this increase.

45 te, geranylgeranyl pyrophosphate (GGPP), and farnesyl pyrophosphate (FPP), which are lipids downstrea

46 MEV, squalene and ergosterol, as well as the farnesyl pyrophosphate (FPP)-derived side products farne

47 yzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).

48 VA), geranylgeranyl-pyrophosphate (GGPP) and farnesyl-pyrophosphate (FPP), all intermediates in the c

49 e inhibitor GGTI-298, and prenyl substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophos

50 arge number of important molecules including farnesyl pyrophosphate, geranylgeranyl pyrophosphate, ch

51 ived from dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have attracted much biosynthetic

52 from 3,5-dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have not been reported despite he

53 ct of NaPA on LPS-induced iNOS expression by farnesyl pyrophosphate, however, suggests a role of farn

54 ygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells.

55 derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate is an essential requisite for cel

56 Wild type Nm23-H1 had higher geranyl and farnesyl pyrophosphate kinase activities than did mutant

57 Neither farnesyl pyrophosphate nor squalene inhibited statin-ind

58 or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that d

59 to a hydroxyl on the pyrophosphate moiety of farnesyl pyrophosphate, pK(a2) = 7.4.

60 duct formation decreases for C3 fluoromethyl farnesyl pyrophosphate substrates, paralleling the numbe

61 ophosphate (FPP) bound to the target enzyme, farnesyl pyrophosphate synthase (FPP synthase), to guide

62 umoral effects through the modulation of the farnesyl pyrophosphate synthase (FPPS) activity.

63 bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit prote

64 that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, p

65 loning and sequencing of a gene encoding the farnesyl pyrophosphate synthase (FPPS) of Trypanosoma br

66 he 5 alpha-halo-analogues potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values

67 be the isoprene biosynthesis pathway enzyme farnesyl pyrophosphate synthase (FPPS), as indicated by

68 rs of the mevalonate/isoprene pathway enzyme farnesyl pyrophosphate synthase (FPPS), we also compared

69 its most firmly established cellular target, farnesyl pyrophosphate synthase (FPPS).

70 ons of the activity of bisphosphonate drugs, farnesyl pyrophosphate synthase (FPPSase) inhibitors, in

71 Human farnesyl pyrophosphate synthase (hFPPS) controls intrace

72 Human farnesyl pyrophosphate synthase (hFPPS) controls the pos

73 Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keep

74 The human farnesyl pyrophosphate synthase (hFPPS), a key regulator

75 nthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrop

76 al roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-containing b

77 ship study of the inhibition of an expressed farnesyl pyrophosphate synthase enzyme by bisphosphonate

78 nomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor that increases

79 loning and sequencing of a gene encoding the farnesyl pyrophosphate synthase of Trypanosoma cruzi.

80 ntaining bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a key enzyme of the mev

81 ins, including acetyl-CoA acetyltransferase, farnesyl pyrophosphate synthase, and carnitine O-octanoy

82 droxy-3-methylglutaryl coenzyme A reductase, farnesyl pyrophosphate synthase, and cytochrome P-450-51

83 els for HMG-CoA reductase, HMG-CoA synthase, farnesyl pyrophosphate synthase, and squalene synthase,

84 mRNA levels for all of these enzymes, except farnesyl pyrophosphate synthase, indicating a specific l

85 The protein (T. cruzi farnesyl pyrophosphate synthase, TcFPPS) is an attractiv

86 it the dimeric organization also observed in farnesyl pyrophosphate synthase.

87 from the chain elongation site described for farnesyl pyrophosphate synthase.

88 lonate/isoprene biosynthesis pathway enzyme, farnesyl pyrophosphate synthase.

89 any, IPP and expressed much lower levels of farnesyl pyrophosphate synthase.

90 edronate, in T. b. rhodesiense is the enzyme farnesyl pyrophosphate synthase.

91 stearoyl-CoA desaturase, squalene synthase, farnesyl-pyrophosphate synthase, 3-hydroxy-3-methylgluta

92 e to HMG-CoA reductase (upstream enzyme) and farnesyl-pyrophosphate synthase, respectively.

93 Farnesyl pyrophosphate synthetase (FPPS) synthesizes far

94 Farnesyl pyrophosphate synthetase (FPS; EC 2.5.1.10) pro

95 p13(II) localizes to mitochondria, binds farnesyl pyrophosphate synthetase, an enzyme involved in

96 e isoprenoid biosynthetic pathway leading to farnesyl pyrophosphate, the immediate molecular precurso

97 pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations

98 A PFT that transfers the farnesyl group from farnesyl pyrophosphate to a cysteine that is 4 residues

99 e gene encoding a phosphatase which converts farnesyl pyrophosphate to farnesol.

100 actions of the universal alicyclic precursor farnesyl pyrophosphate to produce more than 300 differen

101 lium roqueforti catalyzes the cyclization of farnesyl pyrophosphate to the bicyclic sesquiterpene ari

102 Nm23 proteins can phosphorylate geranyl and farnesyl pyrophosphates to give triphosphates.

103 orphologic and cytoskeletal changes, whereas farnesyl pyrophosphate was ineffective.

104 carboxamide ribotide (ZMP), GDP-mannose, and farnesyl pyrophosphate were found to be rapidly altered

105 se (FPS; EC 2.5.1.10) produces the 15-carbon farnesyl pyrophosphate which is utilized in the synthesi